首页 | 本学科首页   官方微博 | 高级检索  
检索        

BDT和VADT方案治疗多发性骨髓瘤的临床研究
引用本文:王秀明,郭振清,崔中光,孟凡军,李广伦,赵洪国.BDT和VADT方案治疗多发性骨髓瘤的临床研究[J].齐鲁医学杂志,2011,26(3):216-218.
作者姓名:王秀明  郭振清  崔中光  孟凡军  李广伦  赵洪国
作者单位:青岛大学医学院附属医院血液科,山东青岛,266003
摘    要:目的比较BDT与VADT方案治疗多发性骨髓瘤(MM)的疗效及不良反应。方法回顾分析72例MM病人,其中24例病人(初治13例,复发难治11例)接受BDT(硼替佐米联合地塞米松、沙利度胺)方案治疗,48例病人(初治36例,复发难治12例)接受VADT(长春地辛联合表柔比星、地塞米松、沙利度胺)方案化疗。所有病人均接受4~6个疗程治疗后进行全面评价,自动放弃治疗、疗程不符合标准以及失访病人不计入。结果 BDT组和VADT组的总完全缓解(TR)率分别为68.42%和35.42%,初治病人TR率分别为80.00%、44.44%,复发难治病人TR率分别为55.56%、8.33%,两组比较差异均有显著性(2χ=3.965~5.996,P<0.05);两组的总体有效(RR)率分别为89.47%和70.83%,两组比较差异无显著性(P>0.05)。两组初治病人达到最大反应中位疗程数分别为3和5个,复发难治病人分别为4和7个。常见的不良反应有骨髓抑制、消化道症状、肝肾功能损害、周围神经病变、乏力、血栓形成、血凝异常、带状疱疹病毒感染、精神症状、皮疹等,两组比较差异无显著意义(P>0.05)。结论 BDT方案治疗MM比VADT方案有较高的TR率,对复发难治性MM效果明确,且起效更快,副作用多可耐受,值得临床推广。

关 键 词:多发性骨髓瘤  硼替佐米  沙利度胺  治疗结果

CLINICA LSTUDY OF BDT AND VADT REGIMEN IN THE THERAPY OF MULTIPLE MYELOMA
WANG XIU-MING,GUO ZHEN-QING,CUI ZHONG-GUANG,MENG FAN-JUN,LI GUANC-LUN,ZHAO HONG-GUO.CLINICA LSTUDY OF BDT AND VADT REGIMEN IN THE THERAPY OF MULTIPLE MYELOMA[J].Medical Journal of Qilu,2011,26(3):216-218.
Authors:WANG XIU-MING  GUO ZHEN-QING  CUI ZHONG-GUANG  MENG FAN-JUN  LI GUANC-LUN  ZHAO HONG-GUO
Institution:WANG XIU-MING,GUO ZHEN-QING,CUI ZHONG-GUANG,MENG FAN-JUN,LI GUANG-LUN,ZHAO HONG-GUO(Department of Hematology,The Affiliated Hospital of Qingdao University Medical College,Qingdao 266003,China)
Abstract:Objective To compare the efficacy and adverse effects of bortezomib-dexamethasone-thalidomide(BDT) regimen with vincristine-epirubicin-dexamethasone-thalidomide(VEDT) regimen for multiple myeloma(MM). Methods A retrospective analysis was done in 72 MM patients,of whom,24(initial treatment 13 cases;recurrent and refractory 11) received BDT regimen;48(initial treatment 36;recurrent and refractory 12) treated with VEDT.All the patients were appraised after 4-6 courses of therapy,those who gave up the treatment...
Keywords:multiple myeloma  bortezomib  thalidomide  treatment outcome  
本文献已被 CNKI 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号